CRBP - Corbus Pharmaceuticals Holdings, Inc.
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 8.39 |
| Open | 8.44 |
| Bid | 7.95 x 3200 |
| Ask | 8.20 x 900 |
| Day's Range | 7.95 - 8.50 |
| 52 Week Range | 3.29 - 8.78 |
| Volume | 1,105,463 |
| Avg. Volume | 1,284,373 |
| Market Cap | 576.299M |
| Beta (5Y Monthly) | 1.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.14 |
| Earnings Date | May 11, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.57 |
Fair Value
Related Research
- GlobeNewswire
Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress
Phase 2 systemic sclerosis (SSc) analyses show ACR CRISS score correlates with improvements from baseline in how patients feel and function through two years in the lenabasum.
- GlobeNewswire
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
Topline data on schedule for Q3 2020Reduction in pulmonary exacerbations (PEx) as primary endpoint Study enrolled 426 participants regardless of CFTR mutation or background.
- TipRanks
2 “Strong Buy” Small-Cap Stocks That Could See Outsized Gains
As the number of new COVID-19 infections spikes, so has market volatility. An uptick in cases in the U.S. and China has spurred the latest burst of swings, with both the S&P 500 and Dow Jones following up their three-session winning streaks by heading back to the red on Wednesday. That being said, one group of stocks has been steadily gaining traction. Small-caps, or names with market caps below $2 billion, have led the pack, with the Russell 2000’s rebound from its March 23 low point exceeding the S&P 500’s gain over the same time period.Taking all of this into consideration, we set out to find compelling small-cap stocks that combine a low cost of entry with the Street’s backing. Using TipRanks’ database, we pinpointed two that fit the bill. Not only are the tickers currently going for less than $8 apiece, but each has also received enough bullish support from analysts to earn a “Strong Buy” consensus rating. The upside potential at play here isn’t too shabby, either.ContraFect (CFRX)Operating within the biotech space, ContraFect is primarily focused on developing biologic therapies for drug-resistant infectious diseases, especially those treated in hospital settings. With multiple key near-term catalysts, some analysts believe that at $6.50 per share, its price tag reflects an attractive entry point.Writing for Cantor, analyst Louise Chen describes her enthusiasm for this name as “infectious." Pointing to the readout of Phase 3 data for exebacase (CF-301), the advancement of CF-370 into and through clinical trials and the identification of an IND candidate for its amurin peptide program, she believes these events could prompt upwards earnings revisions, should the results be favorable.Looking more closely at the first, exebacase is a direct lytic agent (DLA), or group of enzymes targeting the bacterial cell wall leading to immediate bacterial cell death. The candidate showed that it can produce a significant improvement in MRSA patient responder rates, and demonstrated robust levels of safety and tolerability in a Phase 2 study. As a result, Chen thinks the chance of positive results in the Phase 3 DISRUPT study is high.Expounding on this, Chen stated, “We estimate U.S. base case peak sales could be ~$700 million by year five, and in the upside case, peak sales could be ~$1.5 billion. CF-301 has Breakthrough Therapy designation for MRSA bacteremia, Fast Track designation and streamlined development from the FDA.” She added, “Positive Phase 3 data from one study could be enough for U.S. FDA approval.”Speaking to the strength of CFRX’s pipeline, resistant infections increase mortality and costs, and Chen estimates that global mortality was 700,000 in 2016, with this figure expected to reach 10 million in 2050. On top of this, her projections put annual costs in the U.S. at $20 billion and at €1.5 billion in the EU. “New anti-infectives need: 1) superiority data vs. SoC, 2) to show a mortality benefit and 3) to show positive health economics. Currently approved antibiotics do not check these boxes, while CFRX's pipeline will address all these aforementioned factors,” the analyst explained.To this end, the analyst rates ContraFect an Overweight along with a $15 price target. This target implies shares could soar 135% in the next year. (To watch Chen’s track record, click here) All in all, other analysts are on the same page. 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Meanwhile, the $16.33 average price target, which is more aggressive than Chen’s, puts the upside potential at 156%. (See ContraFect stock analysis on TipRanks)Corbus Pharmaceuticals (CRBP)The second stock on our list is Corbus Pharmaceuticals, which develops innovative therapeutics to treat inflammatory and fibrotic diseases. Based on its promising programs, several analysts are getting on board.Representing BTIG, analyst Dae Gon Ha tells investors that this name has been flying relatively under-the-radar. However, given the potential of its lead candidate, lenabasum, this could change.Data from the Phase 3 RESOLVE-1 study evaluating the therapy in systemic sclerosis (SSc) is set to come this summer. Even though the study has been controversial due to the change in endpoint, the analyst argues that “on balance see the change as logical grounded on empirical evidence and physician opinion.” Ha added, “The optics of a changed endpoint notwithstanding, we think the upcoming study is sufficiently powered (>95%) to show clinical efficacy combined with a favorable safety profile.”On top of this, the candidate is also being assessed as a treatment for dermatomyositis (DM). “Behind SSc, DM represents another rare rheumatic disease with a significant market opportunity. Similar to SSc, promising Phase 2 findings were followed with a Phase 3 trial implementing some adjustments (i.e., primary endpoint). Yet despite the differences between SSc and DM, shared features such as multi-organ involvement, skin manifestations, and rampant inflammation suggest that SSc efficacy may provide some readthrough to the probable outcome in DM,” Ha commented.It should also be noted that CRBP has ongoing trials in cystic fibrosis (CF) and systemic lupus erythematosus (SLE), which are being funded externally by the CFF and NIH, respectively. In addition, when comparing the company to Chemocentryx, Ha thinks that if the SSc data de-risks DM, it will imply that CRBP has “an attractive risk/reward profile”.Everything that CRBP has going for it prompted Ha to join the bulls. Initiating coverage with a Buy recommendation, the analyst also set the price target at $22. Should the target be met, a twelve-month gain of 180% could be in store. (To watch Ha’s track record, click here) Turning now to the rest of the Street, other analysts also take a bullish approach. CRBP’s Strong Buy consensus rating breaks down into only Buys, 4 to be exact. The average price target of $26.50 suggests shares could skyrocket 237% from the current share price of $7.82. (See Corbus stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- Zacks
Is the Options Market Predicting a Spike in Corbus Pharmaceuticals (CRBP) Stock?
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
- Zacks
Is Corbus Pharmaceuticals (CRBP) Stock a Solid Choice Right Now?
Corbus Pharmaceuticals (CRBP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- GlobeNewswire
Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
Phase 2b study of lenabasum for treatment of cystic fibrosis enriched for patients at high risk of pulmonary exacerbationsStudy on target for data readout in late summer 2020.
- Simply Wall St.
Will Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
Topline data on schedule for summer 2020Systemic sclerosis (SSc) is a rare, serious and life-threatening autoimmune disease affecting ~200,000 people in the U.S., EU and.
- GlobeNewswire
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
First abstract highlights pre-clinical data linking lenabasum’s mechanism of action to inhibiting inflammasome activationSecond abstract outlines baseline characteristics of.
- Thomson Reuters StreetEvents
Edited Transcript of CRBP earnings conference call or presentation 11-May-20 12:30pm GMT
Q1 2020 Corbus Pharmaceuticals Holdings Inc Earnings Call
- Zacks
Corbus Pharmaceuticals (CRBP) Moves to Buy: Rationale Behind the Upgrade
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Norwood, MA, May 15, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering.
- Zacks
Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't?
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
- GlobeNewswire
Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates
Topline results for lenabasum Phase 3 RESOLVE-1 study in systemic sclerosis remain on schedule for summer of 2020, followed by Phase 2b study data in cystic fibrosis Phase 1.
- GlobeNewswire
Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020
- Management to host conference call and webcast on Monday, May 11 at 8:30 a.m. ET- NORWOOD, MA, May 04, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”.
- GlobeNewswire
Viela Bio Announces Election of Rachelle Jacques to its Board of Directors
GAITHERSBURG, Md., April 30, 2020 -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today.
- GlobeNewswire
Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology
These previously presented data demonstrated lenabasum improved efficacy outcomes and underlying disease pathology compared to placebo and had an acceptable safety profile in.
- Simply Wall St.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Shareholders Booked A 86% Gain In The Last Five Years
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking...
- Thomson Reuters StreetEvents
Edited Transcript of CRBP earnings conference call or presentation 12-Mar-20 12:30pm GMT
Q4 2019 Corbus Pharmaceuticals Holdings Inc Earnings Call
- Simply Wall St.
Corbus Pharmaceuticals Holdings, Inc. Just Reported Earnings, And Analysts Cut Their Target Price
There's been a notable change in appetite for Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) shares in the week...
- GlobeNewswire
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results
Topline results for Phase 3 study in systemic sclerosis on schedule for summer of 2020 followed by Phase 2b study results in cystic fibrosis Completed $46 million public.
- ACCESSWIRE
Corbus Pharmaceuticals Holdings, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March ...
- GlobeNewswire
Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director
Dr. Salzmann brings 20 years of industry experience and currently serves as Chief Executive Officer of Immunovant (IMVT), a biopharmaceutical company focused on developing therapies for patients with autoimmune diseases. Prior to joining Immunovant, Dr. Salzmann held various leadership roles at Eli Lilly and Company, where he most recently served as Global Clinical Development Leader for baricitinib (Olumiant®).
- Simply Wall St.
Did Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Insiders Buy Up More Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
- GlobeNewswire
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020
- Management to host conference call and webcast on Thursday, March 12 at 8:30 a.m. ET - Norwood, MA, March 05, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP).
